Keyword: Farxiga

AstraZeneca may be the first pharma to encourage use of the “F-word.” Although in this case, AZ is talking about its diabetes drug Farxiga.

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.

Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.

AstraZeneca needs just one more year to bring itself back to growth, CEO Pascal Soriot promised investors Friday.

A new study shows SGLT2 diabetes drugs can cut the rate of major cardiovascular events in patients new to treatment.

With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow, and thereafter."

Key non-oncology meds came up big for AstraZeneca in Q3—but that's not what analysts wanted to talk about on the earnings conference call.

AstraZeneca’s Farxiga is already battling with its SGLT2 rivals in Type 2 diabetes. But it may have a future in another field, too.

Johnson & Johnson’s Invokana is losing ground to its biggest rival—and fast.

Amputations? Those are a problem specific to Johnson & Johnson's Invokana alone, the company's SGLT2 rivals contest.